VANDA PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
VANDA PHARMACEUTICALS INC. (VNDA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.95 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-12
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $3.57, a 32.39% decline year-over-year.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $5.28, a 41.01% decline year-over-year.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $8.95, a 56.20% increase year-over-year.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $2.95, a 16.43% decline from fiscal 2023.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $3.53, a 31.85% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $5.18, a 41.86% decline from fiscal 2021.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $8.91, a 61.12% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-12-31 | $2.95 10-K · filed 2026-02-12 | |||||
| 2024-09-30 | $2.95 10-Q · filed 2025-10-30 | |||||
| 2024-06-30 | $2.95 10-Q · filed 2025-07-31 | |||||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | |||||
| 2023-12-31 | $3.53 10-K · filed 2026-02-12 | |||||
| 2023-09-30 | $3.53 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | $3.53 10-Q · filed 2024-08-01 | |||||
| 2023-03-31 | $3.57 10-Q · filed 2024-05-09 | |||||
| 2022-12-31 | $5.18 10-K · filed 2025-02-14 | |||||
| 2022-09-30 | $5.18 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | $5.18 10-Q · filed 2023-07-28 | |||||
| 2022-03-31 | $5.28 10-Q · filed 2023-05-03 | |||||
| 2021-12-31 | $8.91 10-K · filed 2024-02-08 | |||||
| 2021-09-30 | $8.91 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | $8.91 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | $8.95 10-Q · filed 2022-05-06 | |||||
| 2020-12-31 | $5.53 10-K · filed 2023-02-09 | |||||
| 2020-09-30 | $5.53 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $5.65 10-Q · filed 2021-07-29 | |||||
| 2020-03-31 | $5.73 10-Q · filed 2021-05-06 | |||||
| 2019-12-31 | $10.19 10-K · filed 2022-02-24 | |||||
| 2019-09-30 | $10.34 10-Q · filed 2020-10-29 | |||||
| 2019-06-30 | $11.16 10-Q · filed 2020-08-06 | |||||
| 2019-03-31 | $11.50 10-Q · filed 2020-05-07 | |||||
| 2018-12-31 | $10.66 10-K · filed 2021-02-11 | |||||
| 2018-09-30 | $10.66 10-Q · filed 2019-11-07 | |||||
| 2018-06-30 | $10.40 10-Q · filed 2019-08-01 | |||||
| 2018-03-31 | $10.40 10-Q · filed 2019-05-03 | |||||
| 2017-12-31 | $7.81 10-K · filed 2020-02-26 | |||||
| 2017-09-30 | $7.81 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | $7.81 10-Q · filed 2018-08-02 | |||||
| 2017-03-31 | $7.84 10-Q · filed 2018-05-02 | |||||
| 2016-12-31 | $4.53 10-K · filed 2019-02-19 | |||||
| 2016-09-30 | $4.51 10-Q · filed 2017-11-08 | |||||
| 2016-06-30 | $4.44 10-Q · filed 2017-08-03 | |||||
| 2016-03-31 | $4.27 10-Q · filed 2017-05-03 | |||||
| 2015-12-31 | $6.59 10-K · filed 2018-02-15 | $11.74 10-K · filed 2016-02-12 | ||||
| 2015-09-30 | $6.45 10-Q · filed 2016-11-03 | |||||
| 2015-06-30 | $6.15 10-Q · filed 2016-07-28 | |||||
| 2015-03-31 | $6.14 10-Q · filed 2016-05-05 | |||||
| 2014-12-31 | $6.99 10-K · filed 2017-02-17 | |||||
| 2014-09-30 | $7.14 10-Q · filed 2015-11-04 | |||||
| 2014-06-30 | $7.14 10-Q · filed 2015-07-31 | |||||
| 2014-03-31 | $7.90 10-Q · filed 2015-05-07 | |||||
| 2013-12-31 | $6.10 10-K · filed 2016-02-12 | |||||
| 2013-09-30 | $3.98 10-Q · filed 2014-10-27 | |||||
| 2013-06-30 | $3.46 10-Q · filed 2014-08-08 | |||||
| 2013-03-31 | $2.25 10-Q · filed 2014-05-08 | |||||
| 2012-12-31 | $2.08 10-K · filed 2015-03-13 | |||||
| 2012-09-30 | $2.71 10-Q · filed 2013-11-08 | |||||
| 2012-06-30 | $2.75 10-Q · filed 2013-07-31 | $4.41 10-Q · filed 2012-08-03 | ||||
| 2012-03-31 | $4.41 10-Q · filed 2013-05-10 | |||||
| 2011-12-31 | $3.50 10-K · filed 2014-02-25 | |||||
| 2010-12-31 | $5.32 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |